Phase III Results Give Shire’s Vyvanse A Boost In Binge Eating
This article was originally published in The Pink Sheet Daily
Executive Summary
Blockbuster ADHD drug Vyvanse shows efficacy for reducing the frequency of binge eating in two Phase III trials, opening the door to a new indication. Shire plans to file an sNDA by the third quarter of 2014.
You may also be interested in...
APA Update: New Antidepressants Elbow Into Crowded Market
Lundbeck/Takeda unveil pivotal trial data for Brintellix (vortioxetine) in major depression, while Forest pooled analyses shed more light on levomilnacipran in subgroups. Docs don’t think the new drugs are differentiated, but since antidepressant response is so quirky, the prescribing door is still open.
Shire Full Of Hopes For Vyvanse Binge-Eating Indication
First Phase II results in expansion program for the ADHD therapy show strong response in the eating disorder, but the company faces a regulatory challenge in gaining the first approval for the condition.
On A Revenue Roll, Shire Takes Specialist Tactics To “Primary Care” Markets
Shire targets specialist segments of vast primary care populations, with focus on areas of unmet need.